| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
|
N Engl J Med
|
2015
|
13.08
|
|
2
|
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
|
N Engl J Med
|
2016
|
8.53
|
|
3
|
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2007
|
3.40
|
|
4
|
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
|
Cancer
|
2009
|
2.77
|
|
5
|
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
2.10
|
|
6
|
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.81
|
|
7
|
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2005
|
1.79
|
|
8
|
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.
|
Arch Surg
|
2011
|
1.71
|
|
9
|
Impaired interferon signaling is a common immune defect in human cancer.
|
Proc Natl Acad Sci U S A
|
2009
|
1.66
|
|
10
|
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.61
|
|
11
|
Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.60
|
|
12
|
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.57
|
|
13
|
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
|
Cancer
|
2014
|
1.55
|
|
14
|
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
|
Cancer
|
2005
|
1.54
|
|
15
|
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
|
Mod Pathol
|
2012
|
1.52
|
|
16
|
Capecitabine-induced chest pain relieved by diltiazem.
|
Am J Cardiol
|
2012
|
1.40
|
|
17
|
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.
|
Cancer
|
2011
|
1.37
|
|
18
|
Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.
|
Cancer
|
2010
|
1.27
|
|
19
|
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
|
Appl Immunohistochem Mol Morphol
|
2012
|
1.27
|
|
20
|
Long-term survivors of gastric cancer: a California population-based study.
|
J Clin Oncol
|
2012
|
1.16
|
|
21
|
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.
|
J Transl Med
|
2009
|
1.12
|
|
22
|
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA.
|
Oncotarget
|
2013
|
1.03
|
|
23
|
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.99
|
|
24
|
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.
|
Pancreas
|
2013
|
0.93
|
|
25
|
Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement?
|
Ann Surg Oncol
|
2012
|
0.91
|
|
26
|
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
|
Cancer
|
2004
|
0.90
|
|
27
|
Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.
|
Expert Opin Investig Drugs
|
2007
|
0.86
|
|
28
|
Phase II study of imatinib in unresectable hepatocellular carcinoma.
|
Am J Clin Oncol
|
2008
|
0.86
|
|
29
|
Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
|
Ann Surg Oncol
|
2012
|
0.86
|
|
30
|
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
|
Invest New Drugs
|
2006
|
0.85
|
|
31
|
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
|
Invest New Drugs
|
2005
|
0.80
|
|
32
|
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
|
Clin Cancer Res
|
2003
|
0.80
|
|
33
|
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
|
Invest New Drugs
|
2011
|
0.79
|
|
34
|
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
|
Endocr Pract
|
2016
|
0.78
|
|
35
|
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
|
Clin Exp Gastroenterol
|
2010
|
0.78
|
|
36
|
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.
|
HPB (Oxford)
|
2013
|
0.77
|
|
37
|
Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
|
Clin Colorectal Cancer
|
2005
|
0.77
|
|
38
|
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases.
|
Nucl Med Commun
|
2011
|
0.77
|
|
39
|
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
|
Cancer
|
2010
|
0.77
|
|
40
|
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2005
|
0.77
|
|
41
|
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
|
Invest New Drugs
|
2010
|
0.77
|
|
42
|
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
|
Cancer
|
2013
|
0.76
|
|
43
|
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.76
|
|
44
|
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
|
Pancreas
|
2016
|
0.75
|